Citi raised the firm’s price target on Stryker (SYK) to $450 from $411 and keeps a Buy rating on the shares as part of a 2025 outlook for the U.S. medical technology sector. The stocks that outperformed in 2024 followed the traditional med tech path, and Citi expects the same in 2025: launching differentiated products that can be leveraged to the bottom-line, with management teams providing consistent delivery, the analyst tells investors in a research note. Citi names Boston Scientific (BSX) and Insulet (PODD) its top picks for 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK: